Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Adam-Paul Langlinais

Physician Assistant, Surgical Lafayette, LA Physician Assistant

NPI 1437308202 CMS profile 11010387

108 Rue Louis Xiv, Lafayette, LA 70508

Open in the dashboard

General payments

$5,038

74 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adam-Paul Langlinais of Lafayette, LA is reported in the CMS Open Payments database as having received $5,038 across 74 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $269 6
2024 General $1,554 26
2023 General $1,270 14
2022 General $937 12
2021 General $1,009 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam-Paul Langlinais
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Adam-Paul Langlinais were reported at $269. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Adam-Paul Langlinais Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,009 $111 $36–$285 $132
2022 $937 $126 $44–$350 $149
2023 $1,270 $137 $47–$355 $160
2024 $1,554 $146 $49–$384 $164
2025 $269 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $4,366 63 payments
  2. Globus Medical, Inc. $197 5 payments
  3. Abiomed $168 2 payments
  4. Shockwave Medical, Inc $163 1 payment
  5. Philips Electronics North America Corporation $74 2 payments
  6. Cardiva Medical, Inc. $70 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,038 74 payments
Products named General payments · program years 2021–2025
  1. Avalus $1,768 22 payments
  2. Penditure $871 12 payments
  3. Mosaic $739 12 payments
  4. Cardioblate $477 9 payments
  5. Impella $168 2 payments
  6. SHOCKWAVE INTRAVASCULAR LITHOTRIPSY (IVL) SYSTEM WITH THE SHOCKWAVE C2+ CORONARY $163 1 payment
  7. Contour 3D $120 1 payment
  8. EVERA MRI XT DR SURESCAN $108 1 payment
  9. Endurant $87 1 payment
  10. ENDURANT IIS $78 1 payment
  11. Other $358 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

396

Median for Physician Assistant: 241

Drug cost

$7,780

Median for Physician Assistant: $4,110

Branded share of claims

38.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 11 $4,682
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 98 $769
Amiodarone Hcl Generic 59 $611
Valsartan Generic 19 $493
Metoprolol Tartrate Generic 74 $303
Atorvastatin Calcium Generic 20 $253
Oxycodone Hcl Generic 35 $197
Metoprolol Succinate Generic 17 $176
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 22 $165
Clopidogrel Clopidogrel Bisulfate Brand 23 $108

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$18,567

Medicare's payments for the services billed

Medicare patients

106

Average age 71

Services billed

193

49 women, 57 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Arthritis 52%
Atrial fibrillation 50%
Diabetes 44%
Depression 44%
Heart failure 43%
COPD 42%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

74 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record